Ischemic Syndromes

Nov 19, 2024 | ejnmmires.springeropen.com | de Wit |Erik S. G |Amsterdam UMC |Ischemic Syndromes

This study had an open-label design to assess the safety, whole-body biodistribution kinetics, and dosimetry of 99mTc-fucoidan in 10 healthy volunteers consisting of 5 male and 5 female subjects. 99mTc-fucoidan was synthesized according to GMP guidelines as described previously [14] and produced by Eurofins Amatsi Group (Fontenilles, France). The molar activity of 99mTc-fucoidan was 2994 ± 872 MBq/nmol at the end of synthesis, and the radiochemical purity exceeded 95% in every batch.